Alexia Conte
[email protected] | |
Telephone | 02 94375055 |
Location |
Building 13
Floor 2nd Via Adamello 16, Milano |
Member of
Alexia Conte got her PhD title in 2016 in the field of Molecular Oncology. She is currently a Post Doc researcher in Di Fiore’s lab at IEO Experimental Department.
Dr. Conte was born in Bologna and moved to Milan in 2010 to join Di Fiore’s lab. Later she started the PhD program with SEMM, under the supervision of Dr. Sara Sigismund.
From the beginning of her research career, she has been working on the Epidermal Growth Factor Receptor (EGFR). EGFR is important in many cellular activities, including the regulation of processes such as cellular differentiation, migration and proliferation. When EGFR activity is altered, this could lead to cellular dysfunctions and to cancer onset. Indeed, EGFR gene is frequently found amplified or mutated in different human tumors. In particular, her project is focused on the characterization of a molecular process called ubiquitination, that modifies the EGFR and destines it to degradation in condition of high doses of its ligand EGF. Moreover, together with system biologists, they formalized a mathematical model which was able to recapitulate what was observed in biology and to discover interesting and non-obvious behaviors of cancer cells.
Dr. Conte authored different papers and book chapters. In 2016, her PhD thesis was awarded the Marisa Colbacchini first prize for best doctoral thesis, highlighting the high-quality standards of her project. She also received several fellowships funded by distinct Italian charities that supported her work.
Most Relevant Publications
-
Reticulon 3-dependent ER-PM contact sites control EGFR nonclathrin endocytosis.
Science, 2017
-
Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling.
Prog Mol Biol Transl Sci, 2016
-
Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells.
Nat Commun, 2015
-
Threshold-controlled ubiquitination of the EGFR directs receptor fate.
EMBO J, 2013